ArticleJournal of neuroinflammation2026
Methylglyoxal-modification of NLRP3 interrupts NLRP3-NEK7 interaction diminishing inflammasome activation and neuroinflammation.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe NLRP3 inflammasome is a supramolecular complex that mediates pyroptosis and the production of inflammatory cytokines. Aberrant activation of the NLRP3 inflammasome has been implicated in the pathogenesis of various diseases, including cancers, neurodegenerative disorders, metabolic diseases, and autoimmune conditions. Methylglyoxal (MGO), a highly reactive carbonyl compound derived from glycolysis, exerts unclear effects on NLRP3 inflammasome activation. This study aimed to clarify the impact of MGO on NLRP3 inflammasome activity and its underlying mechanism.
methodsNLRP3 inflammasome activation was assessed in vitro in macrophages primed with LPS and stimulated with NLRP3 activators (e.g., nigericin, ATP, or imiquimod), and in vivo using LPS-induced peritonitis and experimental autoimmune encephalomyelitis (EAE) mouse models. Techniques including immunoblotting, immunofluorescent staining, flow cytometry, ELISA, and immunoprecipitation were employed to investigate the effects of MGO on NLRP3 inflammasome activation and its mechanism of action.
resultsMGO significantly suppressed NLRP3 inflammasome activation in macrophages, reducing pyroptosis and mature IL-1β release. It ameliorated inflammatory cell infiltration in the mouse models of LPS-induced peritonitis and EAE. Mechanistically, MGO did not interfere with the potassium efflux or α-tubulin acetylation triggered by NLRP3 inflammasome activators, but rather MGO covalently bonded to NLRP3, interrupted the interaction between NLRP3 and NEK7, which interfered with the assembly of NLRP3 inflammasome and subsequently suppressed pyroptosis and production of mature, bioactive inflammatory cytokines.
conclusionsMGO suppresses NLRP3 inflammasome activation and associated inflammation by covalently binding NLRP3 and disrupting its interaction with NEK7. This reveals a novel mechanism for MGO in innate immunity and identifies NLRP3 as a direct MGO target, suggesting potential therapeutic strategies for NLRP3-driven inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.